These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9310065)

  • 21. Withdrawal of Pneumocystis prophylaxis.
    Zingman BS; Grossberg R
    AIDS; 2008 Jan; 22(2):323-4; author reply 324. PubMed ID: 18097244
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prevention of opportunistic infections in HIV-infected adults].
    Furrer H; Malinverni R
    Ther Umsch; 1998 May; 55(5):302-9. PubMed ID: 9643128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group.
    MMWR Recomm Rep; 1997 Jun; 46(RR-12):1-46. PubMed ID: 9214702
    [No Abstract]   [Full Text] [Related]  

  • 24. Prophylaxis of HIV-associated opportunistic infections: 1997 recommendations.
    Klaus BD; Grodesky MJ
    Nurse Pract; 1997 Dec; 22(12):69-73, 76, 79. PubMed ID: 9437673
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States.
    Chorba TL; Holman RC; Clarke MJ; Evatt BL
    Am J Hematol; 2001 Apr; 66(4):229-40. PubMed ID: 11279632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing early human immunodeficiency virus infection. Agency for Health Care Policy and Research.
    Am J Hosp Pharm; 1994 Apr; 51(8):1003-20. PubMed ID: 7913585
    [No Abstract]   [Full Text] [Related]  

  • 27. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.
    Ann Intern Med; 1997 Nov; 127(10):922-46. PubMed ID: 9382373
    [No Abstract]   [Full Text] [Related]  

  • 28. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America.
    Mofenson LM; Oleske J; Serchuck L; Van Dyke R; Wilfert C
    Clin Infect Dis; 2005 Feb; 40 Suppl 1():S1-84. PubMed ID: 15655768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Latest opportunistic infection prevention guidelines.
    D'Amico R
    Posit Aware; 1998; 9(1):43-4. PubMed ID: 11365000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi.
    Zachariah R; Spielmann MP; Harries AD; Gomani P; Bakali E
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1046-50. PubMed ID: 12546111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines issued for prevention of opportunistic infections in persons with HIV.U.S. Public Health Service and Infectious Disease Society of America.
    Am Fam Physician; 1995 Nov; 52(6):1922, 1924-7. PubMed ID: 7484696
    [No Abstract]   [Full Text] [Related]  

  • 32. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.
    Clin Infect Dis; 2000 Apr; 30 Suppl 1():S29-65. PubMed ID: 10770913
    [No Abstract]   [Full Text] [Related]  

  • 33. Pneumocystis carinii pneumonia (PCP) in HIV-infected African children.
    Zar HJ
    SADJ; 2001 Dec; 56(12):617-9. PubMed ID: 11887451
    [No Abstract]   [Full Text] [Related]  

  • 34. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Vertical HIV-I-transmission. II. HIV-diagnosis in a child].
    Orendi JM; Geelen SP; de Graeff-Meeder ER; van Loon AM; Schuurman R; Boucher CA
    Ned Tijdschr Geneeskd; 1998 Dec; 142(50):2724-8. PubMed ID: 10065236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention and treatment of opportunistic infections].
    Nevot Falcó S; Bartralot Soler J
    Allergol Immunopathol (Madr); 1998; 26(3):144-50. PubMed ID: 9675398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recommendations for fungal opportunistic infections prevention in persons infected with human immunodeficiency virus.
    Popa LG; Popa MI; Zaharia A; Ocneanu M
    Roum Arch Microbiol Immunol; 1999; 58(2):185-95. PubMed ID: 11845456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
    Fichtenbaum CJ
    Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HIV-associated skin diseases. 1: Follow-up and epidemiology of HIV infection, pathogen-induced HIV-associated dermatoses].
    Ramsauer J; Plettenberg A; Meigel W
    Hautarzt; 1996 Oct; 47(10):795-813. PubMed ID: 9036132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.